We are currently completing the final stages of the trial and anticipate a full data analysis completed by the end of this year.īased on the preliminary analysis, we are starting discussions with the FDA to explore whether a dose escalation trial is warranted for the more disabled patients who did not respond to stem cell treatment. While we did observe encouraging trends of improvement in patients treated with stem cells, it must be emphasized that a full data analysis with comparison with the placebo arm remains to be completed to determine whether trends in efficacy are statistically significant. Harris: We are conducting a phase 2 double-blind, placebo-controlled clinical trial testing the efficacy of autologous mesenchymal stem cell neural progenitors (MSC-NPs) administered into the spinal fluid (intrathecally) of patients with SPMS and PPMS. MHE: Please discuss the significance of the Center’s interim stem cell treatment trials, and the next steps in this research. Harris not only discussed the stem cell treatment research, but also other promising MS discoveries. Managed Healthcare Executive® spoke with Violaine Harris, Ph.D., a senior research scientist with Tisch MS Research Center of New York who is also closely involved with the stem cell treatment study. In a preliminary analysis of the data, researchers at the Tisch MS Research Center of New York found that stem cells are the first treatments that improve neurological outcomes in secondary progressive MS (SPMS) and primary progressive MS (PPMS) patients, Tisch MS Research Center of New York, said in a news release.įollowing the stem cell treatments, upper limb dexterity and walking speed improved for 36% of patients, while 30% realized improved muscle strength. Stem cell treatments may result in substantial improvement in muscle strength in patients with multiple sclerosis (MS), according to new research.
0 Comments
Leave a Reply. |